Analysts estimate that bluebird bio will report an earnings per share (EPS) of $-0.37. Anticipation surrounds bluebird bio's announcement, with investors hoping to hear about both surpassing estimates ...
CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...